RAS TESTING
Evidence of wild-type RAS (KRAS and NRAS) status is required before initiating treatment with Vectibix1

  • KRAS and NRAS mutations (collectively referred to as RAS mutations) are found in patients with metastatic colorectal cancer*
  • Mutations may occur at codons 12 and 13 (exon 2), codons 59 and 61 (exon 3), and codons 117 and 146 (exon 4) of
    both KRAS and NRAS
Possible mutations that might occur in KRAS and NRAS genes in patients with metastatic colorectal cancer. Mutations may occur at codons 12 and 13 (exon 2), codons 59 and 61 (exon 3), and codons 117 and 146 (exon 4) of both KRAS and NRAS. Possible mutations that might occur in KRAS and NRAS genes in patients with metastatic colorectal cancer. Mutations may occur at codons 12 and 13 (exon 2), codons 59 and 61 (exon 3), and codons 117 and 146 (exon 4) of both KRAS and NRAS.

The National Comprehensive Cancer Network© (NCCN©) recommends RAS analysis (KRAS and NRAS) of tumour tissue in all patients with metastatic colorectal cancer. The NCCN Colon/Rectal Cancer Panel believes that RAS mutation status should be determined at diagnosis of stage IV disease.6,7†‡

In patients being considered for Vectibix therapy, tumour genetic marker testing should include detection of KRAS (exons 2, 3, and 4) and NRAS (exons 2, 3, and 4) mutations.1,6,7

Download the Vectibix Treatment Management Guide
for more information.
Download

* Clinical significance has not been established. Vectibix is not indicated for patients with RAS (KRAS/NRAS) mutant mCRC or for whom RAS status is unknown.

† Referenced from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Colon Cancer V.2.2023. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed June 26, 2023. To view the most recent and complete version of the guideline, go online to NCCN.org.

‡ Referenced from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Rectal Cancer V.3.2023. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed June 26, 2023. To view the most recent and complete version of the guideline, go online to NCCN.org.

NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way.

KRAS, Kirsten rat sarcoma viral oncogene homologue; mCRC, metastatic colorectal cancer; NCCN, National Comprehensive Cancer Network; NRAS, Neuroblastoma RAS viral oncogene homologue;
RAS, Rat sarcoma viral oncogene homologue.